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Alzheimer’s disease (AD) is a neurodegenerative disease that affects millions of individuals
worldwide and can occur relatively early or later in life. It is well known that genetic
components, such as the amyloid precursor protein gene on chromosome 21, are
fundamental in early-onset AD (EOAD). To date, however, only the apolipoprotein E4
(ApoE4) gene has been proved to be a genetic risk factor for late-onset AD (LOAD). In
recent years, despite the hypothesis that many additional unidentified genes are likely to
play a role in AD development, it is surprising that additional gene polymorphisms
associated with LOAD have failed to come to light. In this review, we examine the role
of X chromosome epigenetics and, based upon GWAS studies, the PCDHX11 gene.
Furthermore, we explore other genetic risk factors of AD that involve X-
chromosome epigenetics.
Keywords: X chromosome, Alzheimer ’s disease, sex chromosome dosage, protocadherin 11,
centromere instabilityINTRODUCTION
In the first two decades of the 21st century, the proportion of individuals living with Alzheimer’s
disease (AD) [AD (MIM: 104300)] has been on the rise with an increasingly aging population.
Today, two basic forms of AD exist, early-onset AD (EOAD) and late-onset AD (LOAD). EOAD
correlates with the occurrence of mutations on specific genes that have given rise to inherited forms
of the disease, whilst LOAD - which occurs later in life - has no specified etiology (Smith, 1998;
Selkoe, 2001). Familial studies have identified a point mutation associated with EOAD on
chromosome 21. This mutation is located in a gene called amyloid precursor protein (APP), and
all members of these families show signs of the Alzheimer’s phenotype at a relatively early stage ofAbbreviations: AD, Alzheimer's disease; EOAD, Early onset AD; GWAS, genome-wide association studies; LOAD, Late onset
AD; NRC/MASC, N-methyl-D-aspartate receptor complex/membrane-associated guanylate kinase-associated signaling
complex; PCDH11X, protocadherin 11; PSD, postsynaptic density; SCD, Sex Chromosome Dosage; Xist, X-inactive-specific
transcript gene; Xi, inactive X chromosome.
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chromosomes 14 and 1 in genes encoding presenilin-1 and
presenilin-2 have also been identified in EOAD (Guven et al.,
2019). Unfortunately, specific genetic determinants that can
explain the high prevalence of LOAD have yet to be identified.
Today we are aware that EOAD comprises only 1-3% of all
AD cases (Smith, 1998; Selkoe, 2001; Bekris et al., 2010). In
LOAD subjects, disease prevalence changes with age; 5% after 65
years of age, 20% after 75 years of age, 30% after 80 years of age
(Bekris et al., 2010). Also women are twice as likely to suffer from
AD than men (Pike, 2017). This prevalence is suggested to be due
to differences in the life expectancy between males and females
and to hormonal status (Vest and Pike, 2013; Pike, 2017). Studies
with twins clearly signal that a strong genetic component is
present in LOAD cases (Gatz et al., 2006; Seripa et al., 2009).
Various genes have been implicated in AD and identified by
using genetic approaches, such as Genome-Wide Association
Studies (GWAS). However, the only “single gene” risk factor for
LOAD without opposition in the research community concerns
the gene encoding apolipoprotein E4 (Giri et al., 2017). In
LOAD, the percentage of individuals carrying the at-risk allele
of the ApoE4 gene was found to be between 20% and 70%,
suggesting that there are additional genetic, and perhaps also
epigenetic, factors that underlie the development of LOAD
(Slooter et al., 1998; Giri et al., 2017). Carrasquillo et al.
(Carrasquillo et al., 2009) found that an alteration of a single-
nucleotide polymorphism (SNP; rs5984894) on the Xq21.3 in a
gene called protocadherin 11 (PCDH11X) in a cohort of women,
was significantly associated with LOAD (Figure 1). Other
GWAS, however, have been unable to confirm the existence of
these connections (Beecham et al., 2010; Wu et al., 2010; Miar
et al., 2011; Chung et al., 2013). We hypothesize that one of the
possible answers to these observed genetic discrepancies is based
on the epigenetics of the X chromosome.
We have previously identified centromere impairment or
premature centromere separation (PCS) of the X chromosome
in neuronal nuclei of the cerebral cortex in AD women (Spremo-
Potparevic et al., 2008). In addition, Yurov et al. discovered X
chromosome aneuploidy in AD-affected neurons (Yurov et al.,
2014), which suggests that premature centromere separation is aFrontiers in Genetics | www.frontiersin.org 2mechanism of X chromosome instability (Spremo-Potparevic
et al., 2008). Epigenetically, chromosome X can be affected by
skewed X chromosome inactivation, asynchronous replication
patterns of the inactive X chromosome (Xi), X-inactivation
escape, aneuploidy, and premature centromere separation. All
these epigenetic X chromosome changes could potentially affect
X chromosome genes through changes in sex chromosome
dosage (SCD), and consequently promote AD pathogenesis
(Amiel et al., 1998; Gribnau et al., 2005; Ahn and Lee, 2008;
Spremo-Potparevic et al., 2008; Hong and Reiss, 2014; Mugford
et al., 2014; Yurov et al., 2014; Bajic et al., 2015a; Balaton and
Brown, 2016; Le Gall et al., 2017; Graham et al., 2019). Raznahan
et al. found recently that sex chromosome dosage not only
influenced the adjacent sex chromosomes X and Y, but also
autosomal gene expression (Raznahan et al., 2018).
The X Chromosome Is Unique
In women, there is a systematic demand to compensate for SCD
by silencing one of the copies of the X chromosome. With two X-
chromosomes, women are more prone to inheriting potentially
deleterious mutations in X-encoded genes, which, because of Xi,
may all be expressed in different cells. The first finding of
inactivation of the X chromosome was reported by Lyon,
(1961). It was found that one of the X chromosomes, paternal
or maternal, was always inactivated, suggesting that an
inactivation mechanism only allows active transcription at one
X chromosome (Splinter et al., 2011). This process of X-
chromosome inactivation (XCI) evolved as a mechanism to
regulate gene dosage. As a compensation mechanism, it does
not affect all genes equally, and those genes that are not affected
are known to escape XCI [termed escapees; (Pessia et al., 2012)].
Human embryos initially have non-random imprinted XCI,
where the X-chromosome from the mother remains active, and
XCI applies only to the X-chromosome inherited from the father.
The imprint is not constant; XCI resets at the embryonic
implantation stage. At this point the XCI reset leaves the
maternal and paternal X open to random inactivation (Sun
and Lee, 2006). Because XCI at this stage is random it causes
most women to be mosaic for two cell lines, one harboring the
active chromosome, the paternal X, and the other the maternal X.
The randomness of this process causes an XCI ratio of
approximately 50%:50% to be associated with the two cell lines
in the female population. However, on rare occasions, in
approximately 9% of the female population, a bias towards one
of the two X chromosomes produces a skewed ratio (> 80%:20%;
(Amos-Landgraf et al., 2006). In this regard, Renault et al.,
analyzed the distribution of X-inactivation patterns (the
relative abundance of the two cell populations) in a large
cohort study of normal females, and reported that human XCI
distribution pattern is more genetically influenced in comparison
to the Xi model, which suggests a completely random selection of
XCI (Renault et al., 2013).
The genetically influenced selection of XCI may be indicative
of mutations in genes (Orstavik, 2009; Shvetsova et al., 2019),
suggesting the inactive X chromosome often harbors the mutated
allele of an X-linked gene. This would mean that with a 50%:50%
XCI ratio, wild type cells generally ameliorate diseaseFIGURE 1 | The genetic position of the PCDH11X on the X chromosome.January 2020 | Volume 10 | Article 1368
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expression of mutated genes can increase disease phenotype
severity, as it is in the case of female hemophilia A (Renault
et al., 2007), and sideroblastic anemia (Cazzola et al., 2000),
where the majority of cells express the mutated allele. Changes in
the XCI ratio where expression of the mutated allele is increased
to exhibit the disease phenotype can also occur, as in Rett
syndrome. In this case, the hemizygous mutation of the
methyl-CpG–binding protein 2 (MeCP2) gene in males causes
lethality, while the MeCP2 heterozygous mutation in females
weakens such phenotypic consequences. It seems that the loss of
MeCP2 function contributes to Rett syndrome, while the gain in
MeCP2 dosage does not necessarily ameliorate the disease
phenotype but may manifest as a less aggressive form in other
neurological diseases. Increased expression of MeCP2 was found
to be associated with other neurological diseases, such as AD and
Huntington’s disease (Amir et al., 1999; Ausio et al., 2014;
McFarland et al., 2014; Maphis et al., 2017).
Xi acquires several features of heterochromatin, such as
hypermethylation, hypercondensation, altered replication
patterns (late vs. early), and depletion of acetylated histones
(Chow and Brown, 2003; Ng et al., 2007). Methylation patterns
have been extensively used to determine the inactive
chromosome (Shvetsova et al., 2019), enabling an analysis of
non-random inactivation processes in diseases that are X
chromosome-linked (Yuan et al., 2015). In our published study
we suggest that changes in the inactivation patterns of the X-
chromosome could have an impact on AD pathogenesis (Bajic
et al., 2015a).BRAIN AND THE X CHROMOSOME
The X chromosome harbors 3-5% of all the genes in a genome
(Skuse, 2005). There has been a debate on howmany genes reside
on the X chromosome and how many genes are expressed in the
brain alone, compared to genes that are X-linked and expressed
in the placenta, testes, muscles, and ovary. It is estimated that
between 1,100 and 1,500 genes are present on the X chromosome
(Skuse, 2005; Laumonnier et al., 2007). By using the Mart View
software it was found that 1,500 X-linked genes are expressed in
the brain, which represent numerous candidate genes that could
be responsible for X-linked brain diseases (Laumonnier et al.,
2007). Many of the proteins expressed from the genes linked to
the X chromosome represent channels, receptors, repair,
transcription factors, and DNA/RNA binding proteins. Most of
these proteins are located in the postsynaptic cleft and
postsynaptic density (PSD) and are regulated through signaling
complexes (Nguyen and Disteche, 2006; Laumonnier et al.,
2007). It is intriguing that even if the X chromosome harbors
3-5% of all the genes, it is responsible for 10% of all diseases with
Mendelian inheritance (Germain, 2006).
Another aspect that makes the X chromosome unique is that
it harbors a higher proportion of brain-expressed miRNAs than
would be expected (Goncalves et al., 2019), with 20% of these
related to autoimmune diseases such as rheumatoid arthritis andFrontiers in Genetics | www.frontiersin.org 3systemic lupus erythematosus (Khalifa et al., 2016). Most of these
miRNA are clustered, for example, miR532/188, miR-221/222,
miR-98/Let7f, and miR-363/106a/20b/92a (DeMarco et al., 2019;
Goncalves et al., 2019). Many of these are also intronic and it is
believed that they are co-transcribed and co-expressed with other
genes linked to chromosome X (deleted X-linked genes) and may
be susceptible to SCD, skewing, and Xi escape processes. It is
important to point out that inflammation and altered immunity
are features of AD (Forloni et al., 1992; Hauss-Wegrzyniak et al.,
1998; Eikelenboom et al., 2000; McGeer and McGeer, 2002;
Castellani et al., 2008; Krstic et al., 2012; Bajic et al., 2015c;
Regen et al., 2017).
How these X-linked genes interact with genes controlling the
immune system in AD is still unknown. For individual genes
involved in diseases of the brain, a more complex hypothesis is
that interplay occurs in disease genes embedded in multiprotein
neuronal complexes. Many of the most important components of
neuronal complexes are encoded on the X chromosome
(Laumonnier et al., 2007). Such complexes, which are essential
for neuronal plasticity, cognitive processes, and cell signaling, are
thought to be in the PSD cleft (Muddashetty et al., 2011;
Yudowski et al., 2013). Taking N-methyl-D-aspartate receptor/
membrane-associated guanylate kinase-associated signaling
complex/(NRC/MASC) as an example; combining its 185
proteins and with the other proteins in PSD gives a total of
1100 proteins. The X chromosome plays an essential role, and
the percentage of genes related to synaptic plasticity, some 86%
of all the genes in NRC/MASC are genes linked to chromosome
X (Grant et al., 2005; Laumonnier et al., 2007). It is interesting
that these genes are also presented or expressed in human
cognitive disorders (Grant et al., 2005; Pocklington et al., 2006;
Fernandez et al., 2009; Tam et al., 2009). An analysis of the
number of altered proteins in X-linked mental retardation
disorders shows that from 69 genes currently known, 19 (or
28%) of these genes belong to postsynaptic proteins
(Laumonnier et al., 2007). The same pattern is conserved in
the mouse X chromosome, and this suggests a network of
multiprotein complexes functioning as integrated entities or
complex molecular machines. If one component of this
complex machinery is disrupted, the whole complex/network
fails thus impairing the overall role of the multiprotein complex
in processes of cognition (Grant et al., 2005; Nguyen and
Disteche, 2006; Pocklington et al., 2006; Laumonnier et al.,
2007; Fernandez et al., 2009; Tam et al., 2009).
X-Linked miRNA and the Brain
The X chromosome is enriched in ncRNAs and harbors several
miRNAs essential to brain function (Goncalves et al., 2019). It is
important to note that miRNAs not only affect mRNA through
translation repression but also work through other ncRNAs,
such as lncRNAs and circRNAs, affecting downstream genes
(Khalifa et al., 2016; DeMarco et al., 2019; Goncalves et al., 2019).
Bian et al. revealed that a miRNA located on the X chromosome,
a miR-374 family member, plays a role in cell growth and
differentiation not only in various cancers, but also in AD.
This miR-374 member is located at the X chromosomeJanuary 2020 | Volume 10 | Article 1368
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signaling pathways (Bian et al., 2019). Importantly, the PTEN
pathway is of importance to the progression of AD through a
mechanism that includes altered autophagy (Wani et al., 2019),
mitophagy (Fang et al., 2019), and apoptosis (Cui et al., 2017). A
report by Manzine et al. suggested that miR-374 directly targets
the beta-secretase 1 to regulate the progress of AD, as the levels of
miR-374 were significantly decreased in comparison to controls
(Manzine et al., 2018). In addition to miR-374, several miRNAs
have also been found to correlate to X chromosome-linked
intellectual disability syndrome, and among them are miR-223-
3p, miR-362-5p, miR-504-5p.1, miR-361-5p, miR-505-3p.1 and
miR-505-3p.2. All these miRNAs act as key regulators of genes
linked to chromosome X but also of many autosomal intellectual
disability genes that are connected in a complex network
(Goncalves et al., 2019).
In the future, it is hoped that further work will reveal the
extent to which genes on the X chromosome and miRNAs
expressed in the brain, that together regulate processes
including nervous system development, cell proliferation and
transcription regulation, are altered by X chromosome skewing
and asynchronous replication, which lead to aneuploidy and
deregulation of cohesion dynamics in AD. Also, RNA genes that
are linked to the X chromosome are prone to escape inactivation
of the X chromosome (Peeters et al., 2019). These epigenetic
processes may prove to be gender-associated as research shows
that expression of an X-linked miRNA in rheumatoid arthritis is
more prevalent in women than in men (Khalifa et al., 2016).PCDH11X
Carrasquillo et al. previously identified an SNP (rs 5984894) on
the X chromosome (Xq21,3) in a gene called PCDH11X
(Carrasquillo et al., 2009). This locus is associated with LOAD
in women of European origin from the USA. The PCDH11X
gene encodes the protein, protocadherin 11. Women who are
homozygous for this SNP have a greater risk of developing AD,
not only when compared to women without the SNP, but also
when compared to women that are heterozygotes, and male
hemizygotes (Carrasquillo et al., 2009). Zubenko et al. reported
that the DXS1047 genotype is correlated with AD (Zubenko
et al., 1999) and that this genotype is associated with the
PCDH11X gene (Zubenko et al., 1998). The results from
the same authors indicate an association between the variation
in the PCDH11X gene and the risk of acquiring AD, but these
results have not been confirmed in other GWAS (Beecham et al.,
2010; Wu et al., 2010; Miar et al., 2011). Our suggestion is that
these discrepancies in GWAS results may well be due to the
changes in the epigenetics of the X chromosome.
Does PCDH11X Escape X Inactivation?
Pseudoautosomal genes and functional Y chromosome
orthologues (X-linked genes with Y homology) tend to escape
X inactivation (Disteche et al., 2002; Brown and Greally, 2003).
Sudbrak et al. reported that PCDH11X expression might alsoFrontiers in Genetics | www.frontiersin.org 4escape X inactivation, and this assumption was verified by using
an X chromosome-specific cDNA microarray where elevated
expression of PCDH11X was identified in cells expressing
multiple X chromosomes (Sudbrak et al., 2001). Lopes et al.
indirectly found that PCDH11X expression was higher in women
than in men by looking at CpG islands and their methylation
patterns. By using bisulfite sequencing analysis, the same authors
found the absence of CpG island methylation on both the active
and the Xi chromosomes and that these processes coincide with
possible PCDH11X escape from X inactivation (Lopes et al.,
2006). Another study found that PCDH11X can undergo
asynchronous replication, and that PCDHX11 is also prone to
escape the inactivation process (Wilson et al., 2007). Replication
asynchrony of the X pseudoautosomal locus has been identified
(Vorsanova et al., 2001), and suggests that other genes that
replicate asynchronously are also prone to escape inactivation
(Anderson and Brown, 2005; Carrel andWillard, 2005; Escamilla-
Del-Arenal et al., 2011).
PCDH11X Asynchronous Replication
Xi is associated with a sequence of epigenetic modifications
(Chow and Brown, 2003), and goes through a phase of
changes involving DNA methylation and histone modification
resulting in Xi condensation in a body called the Barr body. This
results in changes in DNA replication – more specifically, the Xi
in the S phase replicates later than its active counterpart.
Imperfect chromosome replication can be a consequence of
“escapees” (genes that escape the inactivation process). Such
genes include hypoxanthine-guanine phosphoribosyltransferase
and Fragile X-chromosome genes that display asynchronicity.
The X-inactive-specific transcript (Xist) gene (important for
inactivation) that is expressed from the Xi also replicates
asynchronously (Boggs and Chinault, 1994; Aladjem and Fu,
2014). Wilson et al. reported that PCDH11X displays replication
asynchrony in both female and male cells (Wilson et al., 2007).
The data from these authors, together with those from others
(Orstavik, 2009), show that a complex relationship exists
between X-inactivation, replication asynchrony, and the status
of expression of individual genes on chromosome X (Bajic et al.,
2008; Bajic et al., 2009).
It thus appears that synchronous replication occurs more
frequently than previously thought, and is found not only
through imprinting, but also through randomized monoallelic
expression, pathologies, and tandem duplications (Wilson et al.,
2007). Clinically, an increase in asynchronous replication
increases the risk in women for aneuploidy (Amiel et al.,
2000). The relationship between centromere instability, control
of replication, and nondisjunction are best exemplified by the
fact that young women that have children with Down’s
syndrome have twice the risk of developing AD (Hardy et al.,
1989; Goate et al., 1990; Fidani et al., 1992; Schellenberg et al.,
1992; Schupf et al., 1994; Petersen et al., 2000; Schupf et al., 2001;
Migliore et al., 2006; Migliore et al., 2009; Iourov et al., 2010;
Goate and Hardy, 2012).
Chromosomes 21, X, and 18 were primarily affected, showing
repeated non-disjunction and centromere impairment (Potter
and Geller, 1996; Geller and Potter, 1999; Petersen et al., 2000;January 2020 | Volume 10 | Article 1368
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Potter, 2016). We suggest that X chromosome replication
asynchrony is likely to lead to accelerated instability of
chromosome X in AD (Bajic et al., 2009).SEX CHROMOSOME DOSAGE (SCD): AN
ENGINE OF STABILITY
The crosstalk that exists between X chromosomes and autologous
genes is a relatively new paradigm that has emerged as a result of
the biology of sex differences, and gives rise to the question of how
SCD shapes the genome function. To explore this, human sex
aneuploidies were analyzed from a genome-wide expression
dataset by Raznahan et al. where they found a dosage sensitivity
of the X-Y chromosome pair resulting in increased expression of
genes that decrease X/Y chromosomal dosage (Raznahan et al.,
2018). The most interesting finding was that X-linked genes were
found to regulate co-expression of networks of autosomal genes
that are SCD-sensitive and, in addition to these findings, suggest
that the autosomal genes and their corresponding networks are
crucial for cellular functions. This highlights the potential of SCD
to affect the occurrence of disease.
The most common aneuploidy in AD is XO mosaicism
(Spremo-Potparevic et al., 2004; Spremo-Potparevic et al.,
2008; Yurov et al., 2014; Spremo-Potparevic et al., 2015). In
respect to SCD and the XO status, Raznahan et al. have
demonstrated up-regulation of the protein networks,
noncoding RNA metabolism, suppression of the cell
cycle, changes in regulation of DNA/chromatin organization,
glycolysis, and response to stress (Raznahan et al., 2018).
Changes in these collective networks through XO and
supernumerary XXY, and XXYY syndromes may enhance the
risk of AD (Raznahan et al., 2018; Graham et al., 2019).
There is a small but constant number of neuronal cells that
express a different number of chromosomes, such as aneuploidy
(Iourov et al., 2006; Yurov et al., 2007; Iourov et al., 2008; Iourov
et al., 2009; Yurov et al., 2014), but also copy number variation
on chromosome 21, which is crucial in AD (Cai et al., 2014),
DNA content variation (Madrigal et al., 2007; Westra et al.,
2010), and LINE elements (Evrony et al., 2012).
Mosaic aneuploidy in the brain revealed that not only was
chromosome 21 affected in AD, but also that the X chromosome
was found to be supernumerary and presumed to be affected
through a mechanism that involves altered cohesion/cohesin
dynamics (Spremo-Potparevic et al., 2004; Spremo-Potparevic
et al., 2008; Bajic et al., 2009; Zivković et al., 2010; Zivkovic et al.,
2013; Yurov et al., 2014; Bajic et al., 2015b; Spremo-Potparevic
et al., 2015; Yurov et al., 2019).
Yurov et al. (2014) suggested that chromosome 21might not be
the only chromosome to influence changes in genome stability of a
neuron, which leads to a cascade of processes that result in
neuronal loss. The finding that affected brains show a two-fold
increase in X chromosome aneuploidy in the hippocampus andFrontiers in Genetics | www.frontiersin.org 5cerebrum - areas of the brainmost affected byAD - suggesting that
altered sex chromosome dosage plays a role in the large scale
genomic variation in neuronal cells in AD compared to controls.
These results have been recently corroborated by the finding that
the sex chromosomes were distinct from autosomes in
the dorsolateral prefrontal cortex and that X chromosome
aneuploidy was associated with a faster rate of cognitive
decline which is a hallmark of AD (Graham et al., 2019).
Therefore, X chromosome aneuploidy may contribute to aging,
but also to processes leading to pathological changes in brains
affected by AD.
Previously we proposed the “post-mitotic state-maintained
protein hypothesis”where we distinguished aneuploization in the
brain as constitutional aneuploidy with non-pathological
diversification of the neurons (Bajic et al., 2015b). These
aneuploidogenic processes are balanced with cohesin and
cohesion-related proteins. Alteration of this balance develops as
a link between neuronal development and chromosomal
instability, intracellular diversity and human brain diseases
including AD (Hong and Reiss, 2014). Looking closely at the
overall somatic mosaicism found in the brain, we, together with
others, suggest thatmicro aneuploidy or segmental aneuploidy is a
more proper measure of changes in gene dosage leading to AD
(Dierssen et al., 2009). These processes are heavily realized when
looking at SCD effects on gene expression in humans (Raznahan
et al., 2018).
An additional complexity of genome mosaicism in the brain
relates to findings concerning DNA and gene copy number
variations. Regional variations of DNA content has been
identified with higher DNA content found in the frontal cortex
and cerebellum compared with other brain regions (Westra et al.,
2010). Copy number variations may be considered as an
independent genetic factor not related to other genomic
changes, suggesting its plays a role in neurodevelopmental
disorders in patients with sex chromosome aneuploidies (Haack
et al., 2013; Le Gall et al., 2017). It has been reported that 11% of
neurons in the brain cortex exhibit a DNA content that is above
the diploid level (Fischer et al., 2012), and similar findings have
also been reported in the AD brain (Ueberham and Arendt, 2005;
Arendt et al., 2010; Yurov, 2017; Barrio-Alonso et al., 2018). These
somatic gene variations in neurons appear to be generated by
chromosome segregation defects. Some of these cells are expelled
by apoptosis, but several cells are introduced as a pool of
variability of the neuronal genome. These cell populations are
thus vulnerable in the sense that they are more prone to genome
instability and thus may contribute to age-related mental
disorders, such as AD. Gómez-Ramos et al. presented distinct
X-chromosome single nucleotide variants from some sporadic AD
samples (Gómez-Ramos et al., 2015). In samples from LOAD
patients, a higher number of single nucleotide variants in genes
present at the X chromosome were identified using exome
sequencing compared to age-matched controls. Two genes that
were not previously described as risk factors, UBE2NL and
ATXN3L, were found to have variants important for the
ubiquitin pathway in LOAD (Gómez-Ramos et al., 2015).January 2020 | Volume 10 | Article 1368
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process. The 3D organization of the genome is correlated to gene
expression in the interphase. In the 3D domain, chromosomes
occupy preferential positions by self-organizing into
topologically-associated domains, which may change due to
the cell lineage or stage of the organism (Laskowski et al.,
2019). There is a possible exchange between the inactive and
active chromosome in gene regulatory information. Cohesin is
indirectly associated with the Xi 3D position in the genome.
Minajigil et al. reported that a reaction between Xist and cohesins
results in the repulsion of the latter from Xi, thus changing its 3D
shape (Minajigi et al., 2015). The Xi is much more complex, and
it also represents a reservoir of genes that could replace mutated
genes from the active X chromosome. At present, this untapped
potential known as the X interactome requires further
investigation (Minajigi et al., 2015). Progress in understanding
the Xist interactome requires more understanding of how it is
used and how epigenetically-regulated long ncRNAs potentially
influence disease. By utilizing a specific technique named iDRiP,
some 200 proteins in the Xist interactome were identifiedFrontiers in Genetics | www.frontiersin.org 6(Minajigi et al., 2015). Most of the proteins are from several
categories, such as cohesins, condesins, topoisomerases, RNA
helicase, histone modifiers, methyltransferases, nuclear matrix
proteins, and nucleoskeletal factors. Cohesin may play a more
important role in the complex relationship between the Xi and
active X chromosome (Minajigi et al., 2015). Even though these
processes are an important mechanism of diversity, alterations
may lead to an increased structural and topological variation of
the genome in the brain, enhancing the susceptibility of affected
neurons to genome instability that may lead to AD (Bajic et al.,
2015b; Graham et al., 2019; Yurov et al., 2019).
A number of publications have reported mislocalization of
some critical proteins responsible for chromatin organization
and epigenetic modifications in brain diseases including AD (Gill
et al., 2007; Lu et al., 2014; Luperchio et al., 2014; Quinodoz and
Guttman, 2014; Guo et al., 2015; Mastroeni et al., 2015; Pombo
and Dillon, 2015; Sen et al., 2015; Winick-Ng and Rylett, 2018).
All these data suggest, that in AD chromatin, organizers are
deregulated and chromatin topology is changed in a manner that
alters gene expression leading to synaptic dysfunction, a majorFIGURE 2 | X chromosome instability, Sex Chromosome Dosage, Topological changes of Chromosomes, and its possible role in AD.January 2020 | Volume 10 | Article 1368
Bajic et al. X Chromosome in Alzheimer’s Diseasepathological change in AD, and consequently neurodegeneration
(Gill et al., 2007; Lu et al., 2014; Luperchio et al., 2014; Quinodoz
andGuttman, 2014; Guo et al., 2015;Mastroeni et al., 2015; Pombo
and Dillon, 2015; Sen et al., 2015; Winick-Ng and Rylett, 2018).
Xist RNA can act as a scaffold for proteins required tomaintain
the inactive state of neurons. It has been shown that it can act as a
repulsion mechanism that expels architectural factors such as
cohesins in order to avoid unwanted chromatin conformation
that could increase unfavorable transcription (Raznahan et al.,
2018). Minajigi et al. suggest that Xi RNA plays an important
role in the organization of how chromosomes are regulated into
chromosome territories and that Xi inactivation is fundamentally
important in these processes (Minajigi et al., 2015). It could be
suggested that X chromosome instability found in ADmay result
in changes in the Xi pattern, Xi escapees, SCD, and consequently
changes in the topological organization, thus altering chromatin
organization that may affect already other genes related to AD
(Figure 2).
The cohesin-associated protein, shugoshin-1, seems to
be fundamental in repressing the accumulation of amyloid-b
and Tau phosphorylation in shugoshin-1 gene (Sgo1)
haploinsufficient mice (Rao et al., 2018).SUMMARY
Conflicting results from studies of the PCDH11X gene in AD
could be explained by cohort size, ethnicity, and environmental
factors per se but also by the influence of X chromosome
epigenetics. Thus, GWAS of sex chromosomes should take into
account any alterations of the epigenetic processes in the X
chromosome (Schurz et al., 2019).Frontiers in Genetics | www.frontiersin.org 7The findings that chromosome X expresses all of the somatic
genomic neuronal variability properties and can de novo express
several epigenetic mechanisms suggest that the X chromosome
instability phenotype may be viewed as an important risk factor
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